# An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®

> **NCT02455024** · — · TERMINATED · sponsor: **Ariad Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Myeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02455024
- **Lead sponsor:** Ariad Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-02
- **Primary completion:** 2019-02-19
- **Final completion:** 2019-02-19
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Business Decision; Insufficient Enrollment
- **Last updated:** 2024-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02455024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02455024, "An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02455024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*